News for Mirum Pharmaceuticals, Inc. (MIRM)

Mirum Pharmaceuticals (MIRM) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Mirum Pharmaceuticals, known by its ticker MIRM, has appointed Doug Sheehy as its new Chief Legal Officer. Before joining Mirum, Sheehy served as the Chief Lega

Summary Mirum Pharmaceuticals Inc (MIRM) announced the appointment of Doug Sheehy, JD, as the new chief legal officer. With nearly two decades of experience in

Mirum Pharmaceuticals, Inc. (NASDAQ: MIRM) today announced the appointment of Doug Sheehy, JD, as chief legal officer. Mr. Sheehy brings nearly two decades of

Mirum Pharmaceuticals (MIRM) appoints Doug Sheehy as Chief Legal Officer. Doug Sheehy brings extensive legal experience from Sonoma Biotherapeutics, Aim

H.C. Wainwright has initiated coverage on Mirum Pharmaceuticals (MIRM) with a Buy rating and set a price target of $73. Mirum is known for its work in developin

Operator: Hello and welcome to Mirum Pharmaceuticals Reports First Quarter 2025 Financial Results. My name is Carla, and I'll be coordinating your call today.

Mirum Pharmaceuticals (MIRM) has received an update from analyst Steven Seedhouse at Raymond James. The analyst maintains a "Strong Buy" rating on the stock, re

Mirum Pharmaceuticals (MIRM) continues to receive a Buy rating from Citi, with a target price set at $72. This comes in light of the company's recent interim re

Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM) today announced that on May 9, 2025, the Compensation Committee of Mirum's Board of Directors granted inducement awa

On May 9, 2025, JMP Securities analyst Jonathan Wolleben reaffirmed a 'Market Outperform' rating for Mirum Pharmaceuticals (MIRM). The analyst maintained the po

Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) Q1 2025 Earnings Conference Call May 7, 2025 4:30 PM ETCompany ParticipantsAndrew McKibben - SVP, Strategic...

[url="]Clearwater Analytics Holdings, Inc[/url][url="].[/url] (NYSE: CWAN) (”œClearwater Analytics” or the ”œCompany”), the most comprehensive technology

Mirum Pharmaceuticals, Inc. (NASDAQ: MIRM) today announced that it will report first quarter 2025 financial results on Wednesday, May 7, 2025. Mirum will also

Mirum Pharmaceuticals (MIRM) to report Q1 2025 financial results on May 7, 2025. Conference call scheduled on the same day at 4:30 p.m. ET. Replay av

Mirum Pharmaceuticals, Inc. (NASDAQ: MIRM) today announced that it will present data at three upcoming medical congresses. Digestive Disease Week (DDW) will be

Mirum Pharmaceuticals (MIRM) to present data at three international medical congresses in May 2025. New data on volixibat from the Phase 2b VANTAGE stud

Mirum Pharmaceuticals receives FDA approval for a new tablet form of its liver disease medication, Livmarli. Analysts project an average price target of

Summary Mirum Pharmaceuticals Inc (MIRM) announced on April 10, 2025, that its Compensation Committee has granted inducement awards to seven new employees. Thes